One patent currently held, every record listed here
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jul 2030. from the record
Of the 3 now held by other companies, 2 name Eurofins Discoverx LLC as their current owner, and 1 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Jul 2030
Next term end
1
Patent families
When these terms end
Each bar runs from grant to computed term end. 2011 to 2030.
US 8,697,387
Methods for Identifying Agents and Their Use for the Prevention of Restenosis
Mar 19, 2030
20152019202320272030
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
Every computed term in this portfolio is shown above.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Mar 2030 · High confidence
Cited by 25 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
now held by Eurofins Discoverx Corporation
Also notable
Ends no later than Oct 2027 · Medium confidence
Renewed at every maintenance window since the 2011 grant; no more fees are due before its term ends in 2027. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Eurofins Discoverx, LLC
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Substituted PYRAZOLO[3.4-D] Pyrimidines as Anti-Inflammatory Agents | 1 in force | to Jul 2030 |
Patents held now
Soonest term end first.
Showing 1 to 1 of 1
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,512,125 | Substituted PYRAZOLO[3.4-D] Pyrimidines as Anti-Inflammatory Agents In force · High confidence | In force | High confidence |
Also on record, not counted in the 1: 3 patents in force now held by others · 8 patents ended · 8 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
1 computed term date comes from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.